Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder

IF 4.6 2区 医学 Q2 IMMUNOLOGY
Bo Wang, Ke Chen, Mingchao Gao, Xi Sun, Wang He, Junyu Chen, Wenjuan Yang, Tenghao Yang, Haide Qin, Honglian Ruan, Hao Huang, Tianxin Lin, Jian Huang
{"title":"Chitinase 3-like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder","authors":"Bo Wang,&nbsp;Ke Chen,&nbsp;Mingchao Gao,&nbsp;Xi Sun,&nbsp;Wang He,&nbsp;Junyu Chen,&nbsp;Wenjuan Yang,&nbsp;Tenghao Yang,&nbsp;Haide Qin,&nbsp;Honglian Ruan,&nbsp;Hao Huang,&nbsp;Tianxin Lin,&nbsp;Jian Huang","doi":"10.1002/cti2.1505","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Lymphatic metastasis, an early stage of the metastasis process, is associated with adverse clinical outcomes in urothelial carcinoma of the bladder (UCB). However, the role of inflammation in triggering lymphatic metastasis remains unclear.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We employed an RNA-sequencing cohort (<i>n</i> = 50) from Sun Yat-Sen Memorial Hospital (SYMH) to identify the most highly upregulated inflammatory gene associated with lymphatic metastasis. Using immunohistochemistry and immunofluorescence analyses, we validated the association of the identified molecule with clinical features and prognosis in an independent UCB cohort (<i>n</i> = 244) from SYMH. We also analysed TCGA-BLCA cohort (<i>n</i> = 408) to identify its potential biological pathways and immune landscape.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In our study, chitinase 3-like 1 (CHI3L1) emerged as a significantly overexpressed proinflammatory mediator in UCB tissues with lymphatic metastasis compared to those without lymphatic metastasis (81.1% vs. 47.8%, <i>P</i> &lt; 0.001). Within UCB tissues, CHI3L1 was expressed in both stromal cells (52.8%) and tumor cells (7.3%). Moreover, CHI3L1<sup>+</sup> stromal cells, but not tumor cells, exhibited independent prognostic significance for both overall survival (<i>P</i> &lt; 0.001) and recurrence-free survival (<i>P</i> = 0.006). CHI3L1<sup>+</sup> stromal cells were positively associated with D2-40<sup>+</sup> lymphatic vessel density (<i>P</i> &lt; 0.001) and the immunosuppressive PD-L1/PD-1/CD8 axis in UCB tissues (all <i>P</i> &lt; 0.05). A bioinformatics analysis also identified a positive association between CHI3L1 expression and lymphangiogenesis or immunosuppression pathways.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our study established a clear association between stromal CHI3L1 expression and lymphatic metastasis, suggesting that stromal CHI3L1 expression is a potential prognostic marker for bladder cancer patients.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 4","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1505","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1505","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

Lymphatic metastasis, an early stage of the metastasis process, is associated with adverse clinical outcomes in urothelial carcinoma of the bladder (UCB). However, the role of inflammation in triggering lymphatic metastasis remains unclear.

Methods

We employed an RNA-sequencing cohort (n = 50) from Sun Yat-Sen Memorial Hospital (SYMH) to identify the most highly upregulated inflammatory gene associated with lymphatic metastasis. Using immunohistochemistry and immunofluorescence analyses, we validated the association of the identified molecule with clinical features and prognosis in an independent UCB cohort (n = 244) from SYMH. We also analysed TCGA-BLCA cohort (n = 408) to identify its potential biological pathways and immune landscape.

Results

In our study, chitinase 3-like 1 (CHI3L1) emerged as a significantly overexpressed proinflammatory mediator in UCB tissues with lymphatic metastasis compared to those without lymphatic metastasis (81.1% vs. 47.8%, P < 0.001). Within UCB tissues, CHI3L1 was expressed in both stromal cells (52.8%) and tumor cells (7.3%). Moreover, CHI3L1+ stromal cells, but not tumor cells, exhibited independent prognostic significance for both overall survival (P < 0.001) and recurrence-free survival (P = 0.006). CHI3L1+ stromal cells were positively associated with D2-40+ lymphatic vessel density (P < 0.001) and the immunosuppressive PD-L1/PD-1/CD8 axis in UCB tissues (all P < 0.05). A bioinformatics analysis also identified a positive association between CHI3L1 expression and lymphangiogenesis or immunosuppression pathways.

Conclusion

Our study established a clear association between stromal CHI3L1 expression and lymphatic metastasis, suggesting that stromal CHI3L1 expression is a potential prognostic marker for bladder cancer patients.

Abstract Image

几丁质酶 3 样 1 的表达与膀胱尿路上皮癌的淋巴转移和预后有关
目的 淋巴转移是转移过程的早期阶段,与膀胱尿路上皮癌(UCB)的不良临床预后有关。然而,炎症在引发淋巴转移中的作用仍不清楚。 方法 我们利用中山大学孙逸仙纪念医院(SYMH)的RNA测序队列(n = 50)来确定与淋巴转移相关的最高度上调的炎症基因。通过免疫组织化学和免疫荧光分析,我们在中山大学孙逸仙纪念医院的独立 UCB 队列(n = 244)中验证了所发现的分子与临床特征和预后的关联。我们还分析了 TCGA-BLCA 队列(n = 408),以确定其潜在的生物通路和免疫格局。 结果 在我们的研究中,与无淋巴转移的 UCB 组织相比,几丁质酶 3-like 1 (CHI3L1) 在有淋巴转移的 UCB 组织中是一个显著过表达的促炎介质(81.1% vs. 47.8%,P < 0.001)。在 UCB 组织中,CHI3L1 在基质细胞(52.8%)和肿瘤细胞(7.3%)中均有表达。此外,CHI3L1+基质细胞(而非肿瘤细胞)对总生存期(P < 0.001)和无复发生存期(P = 0.006)具有独立的预后意义。CHI3L1+ 基质细胞与 D2-40+ 淋巴管密度(P <;0.001)和 UCB 组织中的免疫抑制 PD-L1/PD-1/CD8 轴(均为 P <;0.05)呈正相关。生物信息学分析还发现 CHI3L1 表达与淋巴管生成或免疫抑制通路之间存在正相关。 结论 我们的研究在基质 CHI3L1 表达与淋巴转移之间建立了明确的关联,表明基质 CHI3L1 表达是膀胱癌患者潜在的预后标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical & Translational Immunology
Clinical & Translational Immunology Medicine-Immunology and Allergy
CiteScore
12.00
自引率
1.70%
发文量
77
审稿时长
13 weeks
期刊介绍: Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信